Erector Spinae Plane Block Versus Transcutaneous Radiofrequency in Postherpetic Neuralgia

Sponsor
Diskapi Teaching and Research Hospital
Study ID
NCT07400640
Status
Recruiting
Apply to this trial

Conditions

  • Herpes Zoster
  • Neuropathic Pain
  • Postherpetic Neuralgia

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Erector Spinae Plane Block — PROCEDURE
    1. Ultrasound-guided erector spinae plane block performed under sterile conditions as part of routine clinical care. After skin antisepsis, a 22-G spinal needle was advanced to the erector spinae plane at the level corresponding to the affected dermatome, and a total volume of 10 mL consisting of dexamethasone, bupivacaine, and normal saline was injected. Patients were observed post-procedure according to standard clinical practice. 2. Transcutaneous radiofrequency treatment applied adjacent to the affected dermatome as part of routine clinical care. Adhesive surface electrodes were placed over the painful area, and pulsed electrical stimulation was delivered by the device for 10 minutes per session. The procedure was performed once weekly for two sessions, without any modification for research purposes.

Study Details

This observational study aims to compare the effectiveness of ultrasound-guided erector spinae plane (ESP) block and transcutaneous radiofrequency (RF) treatment in patients with postherpetic neuralgia. Pain intensity and neuropathic pain characteristics will be evaluated using the Visual Analog Scale (VAS) and the Self-Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) score.

Key Dates

First listed
Feb 10, 2026
Start date
Jun 1, 2025
Status verified
Feb 2026
Primary completion
Jun 1, 2026
Completion
Oct 1, 2026

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: Erector Spinae Plane Block
    Patients with postherpetic neuralgia who received ultrasound-guided erector spinae plane block as part of routine clinical care.
  • Arm: Transcutaneous Radiofrequency
    Patients with postherpetic neuralgia who received transcutaneous radiofrequency treatment applied adjacent to the lesion area as part of routine clinical care

Primary Outcome Measure

VAS [ Time Frame: Baseline, post-procedure 1 month ]

Central Contacts

Related Studies